EP3618819A4 - TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES - Google Patents

TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES Download PDF

Info

Publication number
EP3618819A4
EP3618819A4 EP18794381.6A EP18794381A EP3618819A4 EP 3618819 A4 EP3618819 A4 EP 3618819A4 EP 18794381 A EP18794381 A EP 18794381A EP 3618819 A4 EP3618819 A4 EP 3618819A4
Authority
EP
European Patent Office
Prior art keywords
procedures
combinations
novel compositions
targeted drug
drug rescue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18794381.6A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP3618819A1 (en
Inventor
Sreenivasarao Vepachedu
Hans J. MOEBIUS
Anton Bespalov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exciva GmbH
Original Assignee
Exciva GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2017/048748 external-priority patent/WO2018039642A1/en
Application filed by Exciva GmbH filed Critical Exciva GmbH
Publication of EP3618819A1 publication Critical patent/EP3618819A1/en
Publication of EP3618819A4 publication Critical patent/EP3618819A4/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225Polycarboxylic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/485Morphinan derivatives, e.g. morphine, codeine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EP18794381.6A 2017-05-04 2018-05-03 TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES Pending EP3618819A4 (en)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201762501696P 2017-05-04 2017-05-04
PCT/US2017/048748 WO2018039642A1 (en) 2016-08-26 2017-08-25 Compositions and methods thereof
TW106129169A TW201815387A (zh) 2016-08-26 2017-08-28 組成物及其方法
US201862634162P 2018-02-22 2018-02-22
US201862635554P 2018-02-27 2018-02-27
US201862636099P 2018-02-27 2018-02-27
US201862636171P 2018-02-28 2018-02-28
PCT/US2018/030978 WO2018204713A1 (en) 2017-05-04 2018-05-03 Targeted drug rescue with novel compositions, combinations, and methods thereof

Publications (2)

Publication Number Publication Date
EP3618819A1 EP3618819A1 (en) 2020-03-11
EP3618819A4 true EP3618819A4 (en) 2021-01-20

Family

ID=65431106

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18794381.6A Pending EP3618819A4 (en) 2017-05-04 2018-05-03 TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES

Country Status (13)

Country Link
EP (1) EP3618819A4 (enrdf_load_stackoverflow)
JP (2) JP7514078B2 (enrdf_load_stackoverflow)
KR (2) KR102444803B1 (enrdf_load_stackoverflow)
CN (1) CN110831584B (enrdf_load_stackoverflow)
AU (2) AU2018261654A1 (enrdf_load_stackoverflow)
BR (1) BR112019022902A2 (enrdf_load_stackoverflow)
CA (2) CA3062452C (enrdf_load_stackoverflow)
IL (1) IL270326B2 (enrdf_load_stackoverflow)
MA (1) MA49464A (enrdf_load_stackoverflow)
RU (1) RU2760558C9 (enrdf_load_stackoverflow)
TW (1) TWI787260B (enrdf_load_stackoverflow)
WO (1) WO2018204713A1 (enrdf_load_stackoverflow)
ZA (1) ZA201908006B (enrdf_load_stackoverflow)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018204713A1 (en) * 2017-05-04 2018-11-08 Exciva Ug (Haftungsbeschränkt) Targeted drug rescue with novel compositions, combinations, and methods thereof
BR112021018564A2 (pt) * 2019-03-18 2021-11-30 Avanir Pharmaceuticals Inc Métodos de tratamento de sintomas negativos de esquizofrenia usando dextrometorfano deuterado e quinidina
JP7400818B2 (ja) * 2019-06-06 2023-12-19 Jsr株式会社 感放射線性樹脂組成物、レジストパターン形成方法及び化合物
CA3177454A1 (en) 2020-05-19 2021-11-25 Cybin Irl Limited Deuterated tryptamine derivatives and methods of use
CN116473077B (zh) * 2023-05-08 2025-04-11 广东方中高新材料有限公司 一种n,n配位的镓配合物抗菌剂的合成和应用
CN116473073A (zh) * 2023-05-08 2023-07-25 广东方中高新材料有限公司 一种含镓配合物的吡唑醚菌酯增效悬浮制剂及其制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006930A1 (en) * 2002-07-17 2004-01-22 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4241065A (en) * 1979-07-02 1980-12-23 E. I. Du Pont De Nemours And Company Fluoro analogs of hydrocodone and oxycodone useful as analgesics, narcotic antagonists or both
US4950658A (en) * 1988-12-06 1990-08-21 Board Of Trustees Of Southern Illinois Univ. Method of medical treatment of Alzheimer's disease
US5891885A (en) * 1996-10-09 1999-04-06 Algos Pharmaceutical Corporation Method for treating migraine
US6207674B1 (en) * 1999-12-22 2001-03-27 Richard A. Smith Dextromethorphan and oxidase inhibitor for weaning patients from narcotics and anti-depressants
US6335371B1 (en) * 2000-11-28 2002-01-01 Orion Corporation Method for inducing cognition enhancement
US20070099947A1 (en) * 2005-11-03 2007-05-03 Alkermes, Inc. Methods and compositions for the treatment of brain reward system disorders by combination therapy
KR20080097443A (ko) 2006-02-03 2008-11-05 아바니르 파마슈티컬스 덱스트로메토판 및 퀴니딘을 포함하는, 우울, 불안 및 신경퇴행성 장애 치료용 약제학적 조성물
NZ582124A (en) * 2007-05-21 2012-07-27 Reviva Pharmaceuticals Inc Compositions, synthesis, and methods of using quinolinone based atypical antipsychotic agents
US8017623B2 (en) * 2008-07-03 2011-09-13 Trinity Laboratories, Inc. Dextromethorphan hydrochloride
CA2903757A1 (en) * 2013-03-07 2014-09-12 Mindlab LLC Pain medicine combination and uses thereof
JP2016516202A (ja) * 2013-03-15 2016-06-02 キネメッド, インコーポレイテッド バイオマーカー
EP3708168A3 (en) * 2014-09-14 2020-12-09 Avanir Pharmaceuticals, Inc. Combinations of deuterated dextromethorphan and quinidine for the treatment of agitation in dementia
RU2764716C2 (ru) * 2016-08-26 2022-01-19 Экссива Уг (Хафтунгзбешрэнкт) Композиции и связанные с ними способы
WO2018204713A1 (en) * 2017-05-04 2018-11-08 Exciva Ug (Haftungsbeschränkt) Targeted drug rescue with novel compositions, combinations, and methods thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004006930A1 (en) * 2002-07-17 2004-01-22 Avanir Pharmaceuticals Pharmaceutical compositions comprising dextromethorphan and quinidine for the treatment of neurological disorders
WO2014011590A2 (en) * 2012-07-12 2014-01-16 Javitt Daniel C Composition and method for treatment of depression and psychosis in humans

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DOO-YEOUN CHO ET AL: "Selective Inhibition of Cytochrome P450 2D6 by Sarpogrelate and Its Active Metabolite, M-1, in Human Liver Microsomes", DRUG METABOLISM AND DISPOSITION, vol. 42, no. 1, 28 October 2013 (2013-10-28), US, pages 33 - 39, XP055674658, ISSN: 0090-9556, DOI: 10.1124/dmd.113.054296 *
MEIJUAN XU ET AL: "Effect of sarpogrelate hydrochloride on cytochrome P450 2D1/2 in rats", vol. 30, no. 12, 1 January 2014 (2014-01-01), pages 1739 - 1742, XP009519281, ISSN: 1001-1978, Retrieved from the Internet <URL:http://wprim.whocc.org.cn/admin/article/articleDetail?WPRIMID=458713&articleId=458713> DOI: 10.3969/J.ISSN.1001-1978.2014.12.024 *
See also references of WO2018204713A1 *
SOO KYUNG BAE ET AL: "Application of physiologically based pharmacokinetic modeling in predicting drug-drug interactions for sarpogrelate hydrochloride in humans", DRUG DESIGN, DEVELOPMENT AND THERAPY, vol. Volume 10, 1 September 2016 (2016-09-01), pages 2959 - 2972, XP055674632, DOI: 10.2147/DDDT.S109141 *

Also Published As

Publication number Publication date
JP7514078B2 (ja) 2024-07-10
IL270326B (en) 2022-10-01
ZA201908006B (en) 2021-04-28
EP3618819A1 (en) 2020-03-11
CA3062452C (en) 2023-10-24
CA3138116A1 (en) 2018-11-08
JP2020518617A (ja) 2020-06-25
IL270326A (enrdf_load_stackoverflow) 2018-05-03
KR20200062078A (ko) 2020-06-03
CN110831584B (zh) 2023-03-10
CA3062452A1 (en) 2018-11-08
AU2018261654A1 (en) 2019-11-14
RU2019137004A3 (enrdf_load_stackoverflow) 2021-06-04
RU2019137004A (ru) 2021-06-04
RU2760558C2 (ru) 2021-11-29
IL270326B2 (en) 2023-02-01
RU2760558C9 (ru) 2022-02-22
AU2021215274B2 (en) 2022-11-03
JP2023143940A (ja) 2023-10-06
MA49464A (fr) 2020-04-29
BR112019022902A2 (pt) 2020-05-19
TW201842902A (zh) 2018-12-16
CN110831584A (zh) 2020-02-21
KR20210130827A (ko) 2021-11-01
WO2018204713A1 (en) 2018-11-08
TWI787260B (zh) 2022-12-21
AU2021215274A1 (en) 2021-09-02
KR102444803B1 (ko) 2022-09-19

Similar Documents

Publication Publication Date Title
EP3676297A4 (en) COMPOUNDS, COMPOSITIONS AND PROCESSES
EP3463386A4 (en) OLIGONUCLEOTIDES, COMPOSITIONS AND ASSOCIATED METHODS
EP3599868A4 (en) HERBICIDE MIXTURE, COMPOSITION AND PROCESS
EP3436482A4 (en) ANTIBODIES, PHARMACEUTICAL COMPOSITIONS AND METHODS
EP3713530A4 (en) OPHTHALMIC COMPOSITION AND ASSOCIATED ADMINISTRATION SYSTEM
EP3827846C0 (en) COMPOSITIONS, COMBINATIONS AND RELATED METHODS FOR PHOTOIMMUNOTHERAPY
LT3426226T (lt) Oftalmologinė kompozicija
HUE052095T2 (hu) Keratin kezelési készítmények és eljárások
LT3513809T (lt) Medicininė kompozicija, apimanti tivozanibą
EP3704227A4 (en) COMPOSITION AND PROCESS
CL2016002569A1 (es) Anticuerpos, composiciones farmacéuticas y usos de los mismos
EP3618819A4 (en) TARGETED DRUG RESCUE WITH NEW COMPOSITIONS, ASSOCIATIONS AND CORRESPONDING PROCESSES
DK3655017T3 (da) Farmaceutisk sammensætning
BR112016018062A2 (pt) compostos terapêuticos, composição farmacêutica e usos
EP3724211A4 (en) DOSAGE SCHEDULES AND ASSOCIATED COMPOSITIONS AND PROCESSES
LT3273947T (lt) Kompozicija, skirta akių sveikatai
DK3275452T3 (da) Farmaceutisk sammensætning med silibinin
EP3302478A4 (en) PAC-1 COMBINATION THERAPY
DK3583943T3 (da) Farmaceutisk sammensætning
BR112017013012A2 (pt) compostos de indenil, composições farmacêuticas e usos médicos destes
EP3625234A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
DK3236934T3 (da) Farmaceutisk sammensætning, fremstilling og anvendelser deraf
DK3313370T3 (da) Oftalmologisk farmaceutisk sammensætning
EP3738601A4 (en) Cytocidal agent
SMT202400478T1 (it) Composizione farmaceutica

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20191203

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
RAV Requested validation state of the european patent: fee paid

Extension state: MA

Effective date: 20191203

Extension state: TN

Effective date: 20191203

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40015233

Country of ref document: HK

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031135000

Ipc: A61K0031138000

A4 Supplementary search report drawn up and despatched

Effective date: 20201217

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/225 20060101ALI20201211BHEP

Ipc: A61K 47/60 20170101ALI20201211BHEP

Ipc: A61K 9/20 20060101ALI20201211BHEP

Ipc: A61K 47/36 20060101ALI20201211BHEP

Ipc: A61K 31/485 20060101ALI20201211BHEP

Ipc: A61K 31/195 20060101ALI20201211BHEP

Ipc: A61K 45/06 20060101ALI20201211BHEP

Ipc: A61K 31/13 20060101ALI20201211BHEP

Ipc: A61K 31/138 20060101AFI20201211BHEP

Ipc: A61P 25/00 20060101ALI20201211BHEP

Ipc: A61K 31/439 20060101ALI20201211BHEP

Ipc: A61P 9/00 20060101ALI20201211BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20231123